Europe’s first oncology drug discovery accelerator Cumulus Oncology, has appointed four senior figures from the biopharmaceutical industry to help guide the next phase of growth.
Mohamed (Raz) Dewji, Chris Brinsmead, Ian Waddell and Nicola Broughton will join the Edinburgh-headquartered company’s advisory board, to help make decisions on further asset class acquisition and investment. Some will also take executive, strategic or advisory roles in the spin-out companies created as part of the Cumulus business model.
In July this year, St Andrews-based investment firm Eos Advisory led a £1.7m investment round in Cumulus. In September, Cumulus became a key founder of startup biotech company Modulus Oncology, a University of Sheffield spin-out focused on hard-to-treat cancers.
Read more HERE.
